ArticleFrontiers in cellular and infection microbiology2026
Development and validation of a duplex droplet digital PCR assay for the simultaneous detection of cytomegalovirus and Epstein-Barr virus in plasma.
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Human cytomegalovirus (CMV) and Epstein-Barr virus (EBV) are globally prevalent herpesviruses. While typically self-limiting in immunocompetent individuals, infections can cause severe consequences even in this population. In immunocompromised groups, such as transplant recipients and HIV-infected individuals, viral reactivation or coinfection frequently triggers graft rejection, multi-organ invasion, and malignancies, often exhibiting synergistic pathogenicity. Current serological assays are limited by "window periods" and delayed immune responses, while traditional quantitative PCR (qPCR) relies on standard curves for quantification. Consequently, there is an urgent need for precise, interference-resistant methods. This study aimed to develop and validate a duplex droplet digital PCR (ddPCR) assay for the simultaneous, absolute quantification of CMV and EBV in plasma. Methods: Based on the TD-1 platform, a single-tube duplex detection system targeting conserved viral regions was optimized to minimize the "rain effect" and maximize signal-to-noise ratios. Leveraging the absolute quantification capability of ddPCR without standard curves, we compared its performance, including dynamic range and limit of detection (LOD), against a homologous qPCR assay. Clinical validation was conducted using 117 plasma samples from suspected cases, utilizing a commercial qPCR kit as the reference standard. Additionally, tolerance to endogenous interfering substances was assessed. Results: The optimized duplex ddPCR demonstrated high analytical sensitivity, with LODs for CMV and EBV at 7.9 and 6.5 copies/reaction, respectively, which were approximately 6- to 7-fold lower than homologous qPCR (53.4 and 45.6 copies/reaction).No competitive inhibition was observed at low concentrations. In clinical validation, the assay achieved 100% sensitivity and specificity compared to the reference kit, with high quantitative correlation (R Conclusion: This study successfully established a duplex ddPCR assay characterized by high sensitivity, specificity, and robust interference resistance. By enabling precise absolute quantification, it serves as a powerful complement to existing technologies for the early diagnosis and monitoring of CMV and EBV active infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.